Galapagos NV
GLPG32.710USD
-0.110-0.34%
交易中 （美东）报价延迟15分钟
2.16B总市值
亏损市盈率 TTM
关于 Galapagos NV 公司
Galapagos NV 是一家位于比利时的临床阶段生物技术公司。该公司从事具有作用模式的小分子药物的发现和开发。其产品线包括 3 期、2 期、1 期、临床前研究以及囊性纤维化、炎症和其他适应症的发现小分子和抗体项目。该公司专注于开发一系列临床阶段疗法，以增强现有的治疗模式。它结合内部和外部科学，在高度未满足需求的领域开发转化药物，目标是延长全球患者的生命年限并改善其生活质量。它发现哪些蛋白质与类风湿性关节炎、关节炎、炎症性肠病和纤维化等疾病有关。该公司收购了 CellPoint 和 AboundBio，以开发细胞疗法，这是一种针对不同类型癌症的潜在转化疗法。
公司简介
公司代码GLPG
公司名称Galapagos NV
上市日期May 06, 2005
CEOHenry Gosebruch
员工数量704
证券类型Ordinary Share
年结日May 06
公司地址Generaal De Wittelaan L11 A3
城市MALINES (MECHELEN)
上市交易所Euronext Amsterdam
国家Belgium
邮编2800
电话3215342900
网址https://www.glpg.com/
公司代码GLPG
上市日期May 06, 2005
CEOHenry Gosebruch
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Andrew (Andy) Dickinson
Mr. Andrew (Andy) Dickinson
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Elisabeth Svanberg
Ms. Elisabeth Svanberg
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Valeria Cnossen
Ms. Valeria Cnossen
Executive Vice President, General Counsel, Member of the Management Board
Executive Vice President, General Counsel, Member of the Management Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Andrew (Andy) Dickinson
Mr. Andrew (Andy) Dickinson
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
收入明细
单位: EUR更新时间: 7月6日 周日
单位: EUR更新时间: 7月6日 周日
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区EUR
名称
营收
占比
United States
240.79M
87.35%
Europe
34.86M
12.65%
业务
地区
暂无数据
股东统计
更新时间: 6月6日 周五
更新时间: 6月6日 周五
持股股东
股东类型
持股股东
持股股东
占比
Tang Capital Management, LLC
6.01%
Fidelity Management & Research Company LLC
2.25%
BVF Partners L.P.
2.21%
Prosight Capital
2.00%
Deep Track Capital LP
1.12%
Other
86.41%
持股股东
持股股东
占比
Tang Capital Management, LLC
6.01%
Fidelity Management & Research Company LLC
2.25%
BVF Partners L.P.
2.21%
Prosight Capital
2.00%
Deep Track Capital LP
1.12%
Other
86.41%
股东类型
持股股东
占比
Hedge Fund
15.79%
Investment Advisor
3.83%
Investment Advisor/Hedge Fund
2.06%
Research Firm
0.38%
Sovereign Wealth Fund
0.18%
Bank and Trust
0.03%
Other
77.73%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
173
14.68M
22.27%
-2.24M
2025Q1
179
31.47M
47.75%
+14.44M
2024Q4
185
31.50M
47.80%
+9.00M
2024Q3
191
14.15M
21.47%
-8.51M
2024Q2
205
20.48M
31.08%
-2.95M
2024Q1
212
21.04M
31.93%
-2.58M
2023Q4
223
20.26M
30.74%
-3.01M
2023Q3
221
19.52M
29.63%
-4.10M
2023Q2
254
20.05M
30.43%
-5.06M
2023Q1
285
18.55M
28.15%
-1.32M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tang Capital Management, LLC
3.96M
6.01%
+1.42M
+55.71%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.48M
2.25%
-35.02K
-2.31%
Mar 31, 2025
BVF Partners L.P.
1.45M
2.21%
-115.00K
-7.33%
Mar 31, 2025
Prosight Capital
1.31M
2%
+289.90K
+28.28%
Mar 31, 2025
Deep Track Capital LP
741.07K
1.12%
-39.71K
-5.09%
Mar 31, 2025
Finepoint Capital LP
656.59K
1%
-18.18K
-2.69%
Mar 31, 2025
Segall Bryant & Hamill, LLC
651.46K
0.99%
-34.41K
-5.02%
Mar 31, 2025
Hudson Bay Capital Management LP
565.00K
0.86%
+10.70K
+1.93%
Mar 31, 2025
Greenlight Capital, Inc.
482.75K
0.73%
+3.38K
+0.71%
Mar 31, 2025
Renaissance Technologies LLC
330.80K
0.5%
+34.70K
+11.72%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
1.24%
Avantis International Small Cap Equity ETF
0.12%
iShares Biotechnology ETF
0.09%
ActivePassive International Equity ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Avantis Responsible International Equity ETF
0.02%
Avantis International Equity ETF
0.01%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
占比1.24%
Avantis International Small Cap Equity ETF
占比0.12%
iShares Biotechnology ETF
占比0.09%
ActivePassive International Equity ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.05%
Avantis Responsible International Equity ETF
占比0.02%
Avantis International Equity ETF
占比0.01%
iShares Health Innovation Active ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
